Amrol David
Department of Internal Medicine, University of South Carolina School of Medicine, Columbia, SC 29203, USA.
South Med J. 2010 Jun;103(6):554-8. doi: 10.1097/SMJ.0b013e3181de0cf6.
Atopic dermatitis (AD) is a common diagnosis seen in both children and adults, and it is often the first manifestation of atopic disease. Research has shown a strong correlation between serum IgE levels, the severity of atopic dermatitis, and co-existing asthma and/or allergic rhinitis. Omalizumab (Xolair, East Hanover, NJ; Genentech, South San Francisco, CA) is a monoclonal antibody to human IgE and is currently Food and Drug Administration (FDA) approved for the treatment of asthma. We present 3 patients with severe, treatment resistant atopic dermatitis whose cutaneous symptoms significantly improved by treatment with omalizumab.
特应性皮炎（AD）在儿童和成人中都是常见的诊断疾病，且往往是特应性疾病的首发表现。研究表明，血清IgE水平、特应性皮炎的严重程度以及并存的哮喘和/或过敏性鼻炎之间存在密切关联。奥马珠单抗（Xolair，新泽西州东哈嫩；基因泰克公司，加利福尼亚州南旧金山）是一种针对人IgE的单克隆抗体，目前已获美国食品药品监督管理局（FDA）批准用于治疗哮喘。我们报告3例重度、难治性特应性皮炎患者，其皮肤症状经奥马珠单抗治疗后显著改善。
